• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Prostatype Genomics

0.16 SEK-0.93 %27/7 17:29
Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-0.93 %
-10.72 %
-46.77 %
-78.38 %
+40.18 %
-60.51 %
-99.36 %
-99.94 %
-99.88 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
85.23M SEK
Turnover
1.08M SEK
Revenue
594K
EBIT %
-6,555.22 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
31/8
2026

Interim report Q2'26

11/2
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release2026-07-27 18:00

Prostatype Genomics AB offentliggör utfall i företrädesemission av units

Prostatype Genomics
Regulatory press release2026-07-27 18:00

Prostatype Genomics AB announces outcome in rights issue of units

Prostatype Genomics
Regulatory press release2026-07-21 08:00

Sista dag för teckning i Prostatype Genomics AB:s företrädesemission av units är den 23 juli 2026

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-07-21 08:00

Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026

Prostatype Genomics
Third party research2026-07-16 10:11

Prostatype Genomics: Lång väntan i USA - Analysguiden

Prostatype Genomics söker sedan 2024 ersättning från amerikanska Medicare vid användning av gentest på patienter med lokaliserad prostatacancer. Ett positivt besked skulle öppna för inklusion i det enda vårdsystem som betalar för denna typ av gentest...

Prostatype Genomics
Press release2026-07-16 09:40

Analysguiden: ANALYS Prostatype Genomics: Lång väntan i USA

Prostatype Genomics
Regulatory press release2026-07-09 08:30

Idag inleds teckningstiden i Prostatype Genomics AB företrädesemission av units

Prostatype Genomics
Regulatory press release2026-07-09 08:30

The subscription period in Prostatype Genomics AB's rights issue of units begins today

Prostatype Genomics
Regulatory press release2026-07-08 20:45

Prostatype Genomics AB offentliggör informationsmemorandum inför företrädesemission av units

Prostatype Genomics
Regulatory press release2026-07-08 20:45

Prostatype Genomics AB publishes information memorandum prior to rights issue of units

Prostatype Genomics
Regulatory press release2026-07-08 19:45

Prostatype Genomics AB avtalar om top-down-garanti inför kommande företrädesemission av units

Prostatype Genomics
Regulatory press release2026-07-08 19:45

Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units

Prostatype Genomics
Press release2026-07-08 10:00

Investor Studios: Prostatype Genomics VD om Medicare-processen och emissionen

Prostatype Genomics
Press release2026-07-07 11:46

Nyemissioner.se: Läs om Prostatype Genomics som genomför en företrädesemission om 47,4 MSEK

Prostatype Genomics
Regulatory press release2026-06-29 20:00

Styrelsen i Prostatype Genomics AB beslutar om tidigare annonserad företrädesemission av units om cirka 47,4 MSEK

Prostatype Genomics
Regulatory press release2026-06-29 20:00

The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release2026-06-22 18:45

Kommuniké från årsstämma i Prostatype Genomics AB (publ)

Prostatype Genomics
Regulatory press release2026-06-22 18:45

Bulletin from annual general meeting in Prostatype Genomics AB (publ)

Prostatype Genomics
Regulatory press release2026-06-01 10:45

Prostatype Genomics publicerar årsredovisning för 2025

Prostatype Genomics
Regulatory press release2026-06-01 10:45

Prostatype Genomics publishes Annual Report for 2025

Prostatype Genomics